

Longkanker

DAG	TITEL	TIJD	LOKATIE
VRIJDAG 27.09.19	Practical use of liquid biopsy for advanced NSCLC	14:15 -15:15	Malaga Auditorium (Hal 5)
	SCLC: Is it time for novel therapies?	14:15 -15:15	Tarragone Auditorium (Hal 7)
	ESMO-ESTRO Collaborative session: RTCT in stage III NSCLC: Prevention and management of toxicity including the use of immunotherapy	14.00 -15.30	Cartagena Auditorium (Hal 3)
	Current markers in immunotherapy	14:00 -15:30	Barcelona auditorium (Hal 2)
	Proffered Paper 1 - NSCLC, metastatic	16.00 -17.30	Barcelona Auditorium (Hal 2)
	Proffered Paper – CNS tumours	16:00 -17:30	Bilbao Auditorium (Hal 5)
<i>Pfizer sponsored symposium:</i>	Pfizer - Real world data in oncology: It's growing role in research and patient care	18:00 -20:00	Alicante Auditorium (Hal 3)
<i>Roche sponsored symposium:</i>	Cracking the Code of Personalised Healthcare	18:00 -20:00	Tarragona auditorium (Hal 7)
ZATERDAG 28.09.19	Poster discussion session – CNS tumours	08:05 - 09:05	Toledo Auditorium (Hal 5)
	Beyond initial radical treatment of patients with lung cancer	08.30 -10.00	Madrid Auditorium (Hal 2)
	Young Oncologist “boxing” session	09:00 -10:30	Santander Auditorium (Hal 3)
	Next immunotherapy strategies for lung cancer	10.15 -11.45	Madrid Auditorium (Hal 2)
	Poster Display Session 1	12:00 -13:00	Poster Area (Hal 4)
	Common but still rare: What happens when common cancers split into subgroups?	13:00 -14:30	Leon Auditorium (Hal 3)
	<i>MSD sponsored symposium:</i>		
	Redefining Survival Expectations in Lung Cancer	13:00 -14:30	Bilbao auditorium (Hal 5)
	<i>BMS sponsored symposium:</i>		
	The Evolving I-O Landscape in NSCLC	13:00 -14:30	Tarragona auditorium (Hal 7)
	Optimal delivery of immune-oncology (I-O) in advanced NSCLC	14:45 -16:15	Madrid Auditorium (Hal2)
	Proffered Paper 1 – Non-metastatic NSCLC and other thoracic malignancies (SCLC)	16.30 -18.00	Cordoba Auditorium (Hal 7)

ZONDAG 29.09.19	Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies	08.30 - 09.50	Sevilla Auditorium (Hall 2)	
	Oligorecurrent and oligoprogressive NSCLC	10:30 -11:30	Bilbao Auditorium (Hal 5)	
	<i>Medscape Oncology sponsored symposium:</i>	Taking the management of stage III NSCLC to the next level: Is your clinic ready?	13:00 -14:30	Pamplona auditorium (Hal 2)
	<i>Boehringer Ingelheim sponsored symposium:</i>	Making First- and Second-Line Treatment Decisions for Advanced NSCLC	13:00 -14:30	Salamanca auditorium (Hal 3)
	Immunotherapy in thoracic malignancies: What has been achieved in 2019?	14.45 -16.15	Sevilla Auditorium (Hal 2)	
	Poster Discussion – NSCLC, metastatic	16.30 -17.45	Cordoba Auditorium (Hal 7)	
MAANDAG 30.09.19	Proffered Paper 2 - NSCLC, metastatic	08.30 -10.00	Madrid Auditorium (Hal 2)	
	How do we personalise treatment in stage III NSCLC	08:45 -09:45	Tarragona auditorium (Hal 7)	
	Poster Display session 3	12:00 -13:00	Poster Area (Hal 4)	
<i>Pfizer sponsored symposium:</i>	EGFR+, ALK+ and ROS1+ NSCLC: More options, right choices	13.00 -14.30	Tarragona Room (Hal 7)	
<i>Roche sponsored symposium:</i>	Right Treatment, Right Time: Improving Outcomes for Patients with Advanced Lung Cancer	13:00 -14:30	Cordoba auditorium (Hal 7)	
<i>AstraZeneca sponsored symposium:</i>	Evolving the Treatment Practice of Advanced EGFRm NSCLC	13:00 -14:30	Bilbao auditorium (Hal 5)	
<i>Illumina sponsored symposium:</i>	Changing paradigms: The benefits of comprehensive genomic profiling	13:00 -14:30	Santander auditorium (Hal 3)	
	The next horizon in metastatic non-small cell targeted therapy	14:45 -16:15	Madrid Auditorium (Hal 2)	
	How to handle comorbidities in the treatment decision of stages	16:30 -18:00	Pamplona Auditorium (Hal 2)	
DINSDAG 01.10.19	<i>Geen sessies voor longkanker</i>	-	-	
	Congress Highlights 2 – The best of ESMO 2019	09:00 -12:40	Sevilla Auditorium (Hal 2)	

EGFR+, ALK+ and ROS1+ NSCLC: More options, right choices

Monday 30th September 2019, 13:00–14:30

Tarragona Auditorium, Hall 7, Fira Gran Via, Barcelona, Spain



Chair's invitation

On behalf of the faculty, I am pleased to invite you to the Pfizer Oncology satellite symposium '**EGFR+, ALK+ and ROS1+ NSCLC: More options, right choices**'.

As the range of targeted therapies available for oncogene-driven non-small cell lung cancer (NSCLC) continues to grow, physicians need to adjust to a rapidly changing landscape in order to select the best treatment option for each individual patient.

During the symposium, our distinguished faculty will review how the treatment algorithms have evolved for patients with advanced EGFR+, ALK+ and ROS1+ NSCLC, and illustrate how treatment paradigms are rapidly shifting using their real-world experiences and case studies.

Finally, the faculty will discuss and share perspectives on some of the key criteria and factors that need to be considered to inform treatment decisions in routine clinical practice.

My colleagues and I look forward to welcoming you for what promises to be an interesting and engaging symposium.

Federico Cappuzzo, Chair

AUSL della Romagna-Ravenna, Ravenna, Italy

Programme

Chair: **Federico Cappuzzo (Italy)**

13:00–13:05	Welcome and introduction	Federico Cappuzzo (Italy)
13:05–13:15	More options, right choices	Federico Cappuzzo (Italy)
13:15–13:40	EGFR: The dilemma of choice	Daniel Tan (Singapore)
13:40–14:10	ALK and ROS1: Sequencing our options to maximise outcomes	Benjamin Besse (France)
14:10–14:25	Panel discussion	All faculty, facilitated by Federico Cappuzzo (Italy)
14:25–14:30	Summary and close	Federico Cappuzzo (Italy)

Light refreshments will be served prior to the symposium



This meeting is organised and funded by Pfizer.
© 2019 Pfizer Pharma GmbH. All rights reserved.
June 2019. PP-ONC-GLB-0160